Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, August 5, 2025
The Company will host a conference call on Tuesday, August 5, 2025, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com.
A replay of the audio webcast will be available approximately three hours after the conclusion of the call on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. The replay will remain available until Monday, September 29, 2025.
About Novanta
Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables Novanta to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation, the Novanta Growth System, and our customers' success. Novanta's common shares are quoted on Nasdaq under the ticker symbol 'NOVT.'
More information about Novanta is available on the Company's website at www.novanta.com. For additional information, please contact Novanta Inc. Investor Relations at (781) 266-5137 or InvestorRelations@novanta.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Robinhood Sheds Its Meme Stock Skin, Emerges As Full-Fledged Fintech Player
Robinhood Markets, Inc. (NASDAQ:HOOD) shares moved lower on Thursday, despite delivering stronger-than-expected second-quarter results. The stock and cryptocurrency trading platform reported second-quarter revenue of $989.0 million on Wednesday, up 45% year-over-year. The revenue beat a Street consensus estimate of $898.95 million, according to data from Benzinga Pro. Several analysts have weighed in on the stock with updated price forecasts. JP Morgan's Kenneth B. Worthington reiterated a Neutral rating while raising his price forecast from $98 to $ John Todaro maintained a Buy rating and significantly lifted his price forecast from $71 to $120. Meanwhile, Cantor's Brett Knoblauch reaffirmed an Overweight rating and increased his price forecast from $100 to $118. JP Morgan's Take Worthington noted that while Robinhood delivered strong top-line results and kept operating expenses disciplined at $550 million in second quarter of 2025, the quarter also reflected the platform's growing maturity, with multiple products and business lines performing well. The analyst highlighted Robinhood's progress in moving beyond its earlier dependence on meme-stock trading and acknowledged management's solid execution, but pointed out that the platform still lags larger rivals in product breadth and scale. Additionally, he expressed caution regarding the long-term profitability of Robinhood's smaller-sized accounts. The analyst raised the fiscal year 2025 adjusted earnings per share forecast from $1.31 to $1.53. Cantor's Perspective Knoblauch highlighted that the firm's third quarter is off to a strong start, with July net deposits surpassing $6 billion and equity and options volumes expected to hit record highs amid renewed interest in meme stocks. The analyst noted that continued product innovation is driving user growth and expanding Robinhood's share of customer wallets, a trend expected to strengthen with the upcoming launch of Robinhood Banking in the fall. While shares are already up 185% year-to-date compared to the S&P 500's 8%, Knoblauch acknowledged that some investors may feel they missed the opportunity to buy in. Knoblauch projected a 6% increase in crypto volume for 2026, assuming a like-for-like comparison with Bitstamp's 2025 figures, though he expects a down year based on typical crypto market cycles. Needham's Viewpoint Todaro stated that Robinhood is performing strongly across its business, prompting an upward revision in estimates and price target. The analyst expressed increased confidence in the company's ability to drive operating leverage, raising the projected 2026 EBITDA margin to approximately 65%. Todaro also raised the forecast multiple, citing reduced regulatory risks around Robinhood's crypto offerings, including staking, tokenized assets, and prediction markets. The analyst raised the fiscal year 2025 revenue estimate to $4.342 billion from $3.941 billion. Price Action: HOOD shares are trading lower by 1.68% to $104.32 at last check Thursday. Read Next:Image via Shutterstock Latest Ratings for HOOD Date Firm Action From To Feb 2022 Deutsche Bank Maintains Hold Jan 2022 Barclays Maintains Equal-Weight Jan 2022 Rosenblatt Maintains Buy View More Analyst Ratings for HOOD View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Robinhood Sheds Its Meme Stock Skin, Emerges As Full-Fledged Fintech Player originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
21 minutes ago
- Business Wire
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ('Telix' or 'the Company') (NASDAQ: TLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Telix disclosed on July 22, 2025, that it had received a subpoena from the SEC "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates." Based on this news, Telix ADRs fell by more than 10.4% on the next day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
21 minutes ago
- Business Wire
AM Best Affirms Credit Ratings of Jordan Insurance Company Plc.
LONDON--(BUSINESS WIRE)-- AM Best has affirmed the Financial Strength Rating of B (Fair) and the Long-Term Issuer Credit Rating of 'bb+' (Fair) of Jordan Insurance Company Plc. (JIC) (Jordan). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect JIC's balance sheet strength, which AM Best assesses as strong, as well as its adequate operating performance, neutral business profile and marginal enterprise risk management (ERM). JIC's balance sheet strength is underpinned by its risk-adjusted capitalisation, which was at the strongest level as at year-end 2024, as measured by Best's Capital Adequacy Ratio (BCAR). The company's BCAR scores have improved in recent years as a result of measures taken by management to increase risk-adjusted capitalisation, including the suspension of dividend payments and the divesture of certain capital-intensive investments. Nonetheless, a partially offsetting rating factor is JIC's significant holdings of illiquid equity and real estate asset classes, which have been a source of volatility to the company's total equity, and have negatively impacted its regulatory solvency capital ratio. The ratings also consider JIC's moderately high reinsurance dependence for large property and commercial risks, although the associated risks are partially mitigated by a stable reinsurance panel of good credit quality. JIC has a track record of adequate operating performance, evidenced by return-on-equity ratios of approximately 4% over the last five years (2020-2024). The company reported a net profit of JOD 2.3 million in 2024 (2023: JOD 1.8 million), primarily driven by the profitability of its life portfolio, while challenging market conditions in Jordan and the United Arab Emirates translated into a non-life net/net combined ratio of 100.8% (101.7% in 2023 - as calculated by AM Best). Overall operating results have been supported by modest investment income, which translated into an average net investment return of 2.2% over the past five years. However, volatility in fair value movements of investments recognised through other comprehensive income introduced volatility into JIC's total equity over the period. JIC has an established position in Jordan's insurance market, where the company consistently ranks second based on gross written premiums; however, this market remains relatively small by international standards. JIC's insurance services revenue is well-diversified across a range of life and non-life business lines in Jordan. Due to the heavy use of reinsurance on property and other commercial lines, the company's net insurance services revenue is concentrated in motor and medical, although to a lesser extent than its domestic peers. The assessment considers the geographic diversification provided by branch offices in the UAE and, to a lesser extent, Kuwait, together with the multi-year bancassurance agreements in place for the distribution of life insurance products, giving JIC a competitive edge over most of its domestic peers. While JIC demonstrates a sound framework for identifying and managing underwriting-related risks, AM Best considers that risk management capabilities are not commensurate with the company's risk profile in areas including investments and capital management. The company is expected to take further steps to reduce its exposure to these risks over the short to medium term. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.
